SCHEMBL20134963

SCHEMBL20134963

CC(C)(C)OC(=O)N1CCC(c2nn(COCC[Si](C)(C)C)c3cc(Br)cc(Br)c23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
KDM4E B2RXH2 5/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 2/20 0.38
HPGD P15428 5/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 2/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTT P42858 2/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688849 1.00 CNR1 (0.41) CNR1KDM4EMAPTTHRBHPGD
SCHEMBL20135277 0.92 CNR1 (0.40) CNR1KDM4EMAPTTHRBHPGD
SCHEMBL20135368 0.85 CNR1 (0.41) CNR1KDM4EMAPTTHRBHPGD
SCHEMBL20135506 0.84 CNR1 (0.41) CNR1KDM4EMAPTTHRBHPGD
SCHEMBL20135481 0.80 KDM4E (0.45) CNR1KDM4EMAPTTHRBHPGD
SCHEMBL17837846 0.78 HPGD (0.40) CNR1KDM4EMAPTHPGDALDH1A1
SCHEMBL17837585 0.76 ALDH1A1 (0.40) CNR1KDM4EMAPTHPGDALDH1A1
SCHEMBL29900927 0.76 CNR1 (0.43) CNR1KDM4EMAPTTHRBHPGD
SCHEMBL30926199 0.75 KDM4E (0.44) KDM4EMAPTTHRBHPGDALDH1A1
SCHEMBL17838312 0.75 CNR1 (0.43) CNR1KDM4EMAPTTHRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CNR1 2194/4885KDM4E 725/4885MAPT 4505/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CNR1 2870/4885KDM4E 723/4885MAPT 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.